Cargando...
Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-, mechanical ventilation-, and vasopressor-free days at da...
Gardado en:
| Publicado en: | Crit Care Explor |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Lippincott Williams & Wilkins
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7808529/ https://ncbi.nlm.nih.gov/pubmed/33490955 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCE.0000000000000327 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|